pharmaphorum February 12, 2024
Gilead Sciences has beefed up its pipeline with an agreement to buy CymaBay Therapeutics and its seladelpar drug for rare liver disease primary biliary cholangitis (PBC), which has been filed for approval in the US.
The FDA is due to deliver a verdict on seladelpar – which was also in development for non-alcoholic steatohepatitis (NASH) before it failed a phase 3 programme – by 14th August after a priority review. It has been filed for the second-line treatment of adult PBC patients, without cirrhosis or with compensated cirrhosis, who do not respond or are intolerant to ursodeoxycholic acid (UDCA).
The $32.50-per-share offer is a 26.5% premium to CymaBay’s share price on Friday. Trading in the stock was suspended in the...
Today's Sponsors
Today's Sponsor